Ocugen :
OCGN
OCGN
Stock Data
$1.80
$0.07 (4.05%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Ocugen Inc is a pioneering biopharmaceutical company dedicated to developing innovative gene therapies aimed at curing blindness caused by a variety of diseases. With a focus on genetic eye diseases such as retinitis pigmentosa and leber congenital amaurosis, Ocugen's leading product, OCU400, represents a significant advancement in retinal therapy. The company also explores treatments for age-related macular degeneration and diabetic eye diseases through its diverse pipeline, including OCU410 and OCU200. Ocugen's commitment to eye health extends through strategic partnerships, enhancing its research and development capabilities. Headquartered in Malvern, Pennsylvania, Ocugen strives to bring new hope to individuals suffering from vision loss.
All Ocugen Articles
15 Articles